Crossmark

Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective

Crossref DOI link: https://doi.org/10.1007/s10557-021-07276-x

Published Online: 2022-04-25

Published Print: 2023-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xi, Xiaoyu

Wang, Xin

Xie, Wenwen

Jia, Yu

Sanchez, Santiago Zuluaga

Martinez, Laura

Zhao, Quanming https://orcid.org/0000-0003-3457-4953
License Information

Text and Data Mining valid from 2022-04-25

Version of Record valid from 2022-04-25
More Information

Article History

Accepted: 6 October 2021

First Online: 25 April 2022

Declarations

:

: The authors declare that they have no conflict of interest.

: This research did not involve human participants or animals.

: This study did not involve individual participants, so informed consent was exempted.

: This article does not contain any studies with human participants or animals performed by any of the authors.

: Not applicable.

: All authors read and approved the final manuscript.

Document is current

Any future updates will be listed below